Table 1.
Baseline characteristics of Group Health enrollees followed for longstanding persistent atrial fibrillation
| Characteristica | N = 1,317 |
|---|---|
| Demographic characteristics | |
| Age, y, mean (SD) | 69.6 (10.7) |
| Male, % | 50.7 |
| White race, % | 92.9 |
| Group Health enrollment, y, mean (SD) | 22.4 (13.4) |
| Setting of initial AF diagnosis | |
| Outpatient, % | 33.1 |
| Urgent care, % | 11.1 |
| Emergency department, % | 40.4 |
| Inpatient, % | 12.6 |
| Other, % | 1.4 |
| Clinical characteristics | |
| Body mass index, kg/m2, mean (SD) | 29.7 (7.3) |
| Body mass index ≥25.0 (overweight or obese), % | 74.5 |
| Diabetes, % | 16.4 |
| Hypertension, % | 54.8 |
| Systolic blood pressure, mm Hg, mean (SD) | 136.2 (20.4) |
| Diastolic blood pressure, mm Hg, mean (SD) | 76.7 (11.7) |
| Total cholesterol, mg/dL,b mean (SD) | 205.0 (42.6) |
| HDL cholesterol, mg/dL,b mean (SD) | 55.7 (21.5) |
| Total cholesterol:HDL ratio, mean (SD) | 4.0 (1.3) |
| Coronary heart disease, % | 20.8 |
| Valvular heart disease, % | 5.5 |
| Heart failure, % | 6.9 |
| Prior stroke, % | 6.4 |
| Chronic kidney disease, % | 30.8 |
| Medication use just prior to initial AF episode | |
| Statins, % | 21.6 |
| ACE inhibitors or ARBs, % | 31.7 |
| Beta-blockers, % | 28.2 |
| Nondihydropyridine CCBs, % | 4.3 |
| Antiarrhythmics, % | 0.8 |
| Digoxin, % | 2.4 |
Abbreviations: ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HDL, high density lipoprotein
a
Baseline characteristics were determined by medical record review using information recorded up to the day prior to the initial AF episode. 4 participants had missing values for race, 4 for years of Group Health enrollment, and 18 for location of initial AF diagnosis.
b
mg/dL may be converted to mmol/L by multiplying by 0.0259.